Can a new pill ACC017 be safely dosed? a trial seeks answers

NCT ID NCT06278389

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial is testing an experimental drug called ACC017 in healthy adults to see if it is safe and how the body processes it. Researchers are giving different single doses to small groups of volunteers, some receiving a placebo, to find a recommended dose for future studies. The trial also checks whether taking the drug with food changes its effects and whether it interacts with another HIV medication, emtricitabine/tenofovir alafenamide. The goal is to gather essential safety and dosing information before moving to larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ACC017 tablets, an experimental drug, tested alone and with emtricitabine/tenofovir alafenamide (Descovy)
What this could lead to
If successful, this trial could determine a safe dose of ACC017 for future studies, potentially leading to a new treatment option for conditions like HIV.
What could go wrong
This is an early-phase trial in a small group of healthy volunteers, so results may not predict effects in patients. Side effects are possible, and the drug may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Ditan Hospital Capital Medical University

    Beijing, 100015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.